Several preclinical and clinical studies investigating new strategies based on PI3K inhibitors combined with anti-HER2 therapy in HER2-positive and PIK3CA-mutant patients are underway and will explain to what extent can PI3K inhibitors improve the treatment response of PIK3CA-mutant tumours that are resistant to anti-HER2 therapy [50]. Here, ERBB2 is linked to neoplasm.